Navigation Links
Facet Biotech and Trubion Announce Worldwide Collaboration for the Development and Commercialization of TRU-016
Date:8/28/2009

ncing this important program with our partners at Trubion."

"In considering alliance opportunities for TRU-016 we sought to retain meaningful economics in this exciting first-in-class product candidate, while enabling aggressive joint development with a partner who shared our vision and brought complementary experience and resources to the alliance," said Peter Thompson, M.D., FACP, president, CEO and chairman of Trubion. "We are delighted to have Facet as our partner. Coupled with our own strengths in the discovery and development of novel protein therapeutics, their expertise will afford us the opportunity to pursue the clinical development and commercialization of TRU-016 and other CD37-directed therapeutics in the most aggressive manner possible."

Under the terms of the collaboration agreement, Trubion will receive an upfront payment of $20 million and may receive up to $176.5 million in additional contingent payments upon the achievement of certain development, regulatory and sales milestones. The companies will share equally the costs of all development, commercialization and promotional activities and all global operating profits. In addition, Facet will purchase 2,243,649 shares of newly issued Trubion common stock for an aggregate purchase price of $10 million.

About TRU-016

TRU-016 is a novel CD37-directed therapy for the treatment of B-cell malignancies, such as chronic lymphocytic leukemia, or CLL, as well as certain autoimmune and inflammatory disease indications. TRU-016 uses a different mechanism of action than CD20-directed therapies. As a result, its novel design may provide patients with improved therapeutic options and enhance efficacy when used alone or in combination with chemotherapy and/or CD20-directed therapeutics. In June 2009, positive results following preliminary analysis from the Phase 1 clinical trial of TRU-016 for the treatment of CLL were announced. The object
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Facet Solutions Completes 1 Year Follow-up on U.S. Pilot Study
2. The Help Group Launches Multifaceted Autism Awareness Campaign
3. Perrigo Announces FDA Approval for Sulfacetamide Sodium Topical Suspension USP, 10% (Lotion)
4. Archus Orthopedics Performs First Facet Replacement Procedure With an Artificial Disc
5. Facet joint effusion and interspinal ligament edema: major sources of lower back pain
6. TruFUSE(R) Minimally Invasive Facet Fusion Procedure Tops 3,000 Spinal Levels
7. Facet Solutions, Inc. Completes Combination Facet Joint and Disc Replacement Study
8. Facet Solutions, Inc. Appoints Industry Veteran to Board of Directors
9. Facet Solutions, Inc. Expands Executive Management Team
10. Journal of Alzheimers Disease special issue explores multifaceted aspects of AD
11. Facet Solutions AFRS(TM) Implant Demonstrates Positive Clinical Results After One Year Follow Up
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... City, MO (PRWEB) May 04, 2015 ... vice president and chief physician executive, and William C. ... have received and accepted personal invitations from the Secretary ... National Security Forum (NSF) at the Air War College, ... is to expose influential citizens to senior U.S. and ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 The ... Group today launched a new initiative at UC ... next generation of physicians committed to advancing Latino ... Ser Medicos, or Preparing Students to Be Physicians, ... that will provide scholarships, mentorship and internship opportunities, ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Takeda Pharmaceuticals ... billion to settle thousands of Actos lawsuits ( http://www.theactoslawsuitcenter.com/ ... increases the risk that a patient will develop bladder ... 28th, if 95% of those eligible for the Actos ... 9,000 bladder cancer cases currently pending in courts around ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 McNeil ... programs, announces the expansion of coverage for its ... leading provider of industry-tailored insurance and proactive risk management ... Company, we are dedicated to providing our customers with ... their many evolving needs. We are excited to launch ...
(Date:5/4/2015)... 04, 2015 Johnson & Wales University (JWU) ... and science academic center on Wednesday, April 22. , Johnson ... land made available by the re-alignment of Interstate-195. JWU’s new ... Friendship and Chestnut streets in Providence, is scheduled to be ... parcel of land the university purchased in 2012. , “It ...
Breaking Medicine News(10 mins):Health News:Saint Luke’s Health System Leadership Selected to Attend National Security Forum 2Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 2Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 3Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 4Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 5Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 3Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 2Health News:Insurance Leader McNeil & Company Expands Coverage for Emergency Services Insurance Program (ESIP), Launches Enhancements to Property and Casualty Insurance Package 3Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 3
... Ph.D. shares pioneering research with counselors June 6; ... Thanks to a Ph.D. with the,last name ... counseling,sessions including a horse can be more beneficial ... ground-breaking research with other,mental health professionals during her ...
... for the skull projected to climb at double-digit rates, ... according to Millennium Research Group, ... (MRG) US Markets for Craniomaxillofacial (CMF) Devices 2008 report,the plate ... million,in 2007 to nearly $300 million in 2012, driven in ...
... 22 Menstrual migraine, a condition,that affects ... a new supplement to OBG,Management. "Integrating menstrual ... between hormone fluctuation and,migraine, as well as ... Biologic and genetic factors in the pathogenesis ...
... and BREASTCANCER.ORG founder, in,open letter to Congress today about ,Breast Cancer ... ... H.R. 758, WASHINGTON, May 22 "Mandatory drive-through,mastectomies is ... complications," says Dr. Marisa Weiss, a,leading breast oncologist and Founder and ...
... of Rochester Reports SPY Accurately Detects Renal Tumors in the ... ... 22 /PRNewswire-FirstCall/ - Novadaq(R) Technologies Inc.,(TSX: NDQ), a developer of real-time imaging ... results of a clinical study,of the SPY(R) Intra-operative Imaging System in urology ...
... With the ... Internet Users, PARIS, May 22 Publicis ... full-service digital marketing,agency, EmporioAsia. Effective immediately, the agency ... Vincent Kobler heading the renamed,agency. Operating alongside Arc ...
Cached Medicine News:Health News:Equine Partners in Counseling (EPIC) Training Is Changing the Face of Mental Health 2Health News:Craniomaxillofacial Plate & Screw Market To Grow to Almost $300 Million by 2012 2Health News:CME Publication Tackles a Problem that is a Real Headache for Women 2Health News:Drive-Through Mastectomies Threaten Patients' Lives 2Health News:Novadaq's SPY System was Topic of Best Poster in Scientific Session at AUA 2Health News:Novadaq's SPY System was Topic of Best Poster in Scientific Session at AUA 3Health News:Publicis Groupe Acquires EmporioAsia, Leading Digital Agency in China 2Health News:Publicis Groupe Acquires EmporioAsia, Leading Digital Agency in China 3
(Date:5/4/2015)... -- Xencor, Inc. (NASDAQ: XNCR ), a clinical-stage ... treatment of autoimmune diseases, asthma and allergic diseases, ... first quarter ended March 31, 2015 and provided a ... equity offering in February, which raised net proceeds ... strong financial position to advance our lead pipeline ...
(Date:5/4/2015)... 4, 2015  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... the development and commercialization of innovative therapies for ... provided a regulatory update on Zalviso and reported ... 31, 2015. Zalviso Regulatory UpdateOn April ... Division of Anesthesia, Analgesia, and Addiction Products (DAAAP ...
(Date:5/4/2015)... 2015 Transportation Insight, a leading global ... client, DSI Systems Inc., are featured in the ... in the cover story emphasizing technology as the ... editorial illustrates how Transportation Insight implemented its ... growth and success of DSI,s complex supply chain. ...
Breaking Medicine Technology:Xencor Reports First Quarter 2015 Financial and Operating Results 2Xencor Reports First Quarter 2015 Financial and Operating Results 3Xencor Reports First Quarter 2015 Financial and Operating Results 4Xencor Reports First Quarter 2015 Financial and Operating Results 5Xencor Reports First Quarter 2015 Financial and Operating Results 6Xencor Reports First Quarter 2015 Financial and Operating Results 7Xencor Reports First Quarter 2015 Financial and Operating Results 8AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results 2AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results 3AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results 4AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results 5AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results 6AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results 7AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results 8Transportation Insight's Latest Enterprise Logistics Technology Highlighted in Inbound Logistics Magazine 2Transportation Insight's Latest Enterprise Logistics Technology Highlighted in Inbound Logistics Magazine 3
... is pleased to announce the addition of Suzie Williams , CP as ... Regional Clinical Manager.   , , ... http://www.newscom.com/cgi-bin/prnh/20100427/DA94114 ) , , , ... Suzie will be joining us as we were not only impressed by her ...
... & Reed Global Executive Search, a growing recruiting firm with offices worldwide, ... of Managing Director, Biopharmaceutical Life Sciences, effective April 15, 2010 . ... "Dave has outstanding ... recognize how important it is for our clients to work with a ...
Cached Medicine Technology:Suzie Williams, CP Joins Orthocare Innovations as Clinical Services Manager 2Kincannon & Reed Names David G. Jensen as Managing Director, Biopharma Life Sciences 2
... BVM 6500 enables physicians ... determine UEBW (ultrasound estimated ... volume using 3-dimensional V-mode ... was designed to assist ...
... Bard Collagen Implant, the world's leading bulking ... for the treatment of Stress Urinary Incontinence ... surrounding urethral tissue to aid coaptation in ... body's own structure, Contigen Bard Collagen Implant ...
... The Titan™ Inflatable Penile Prosthesis ... designed to be surgically implanted ... management of erectile dysfunction (also ... provides the patient with voluntary ...
... The AMS 650™ and 600M™ malleable ... many patientsespecially those with limited dexterity. These ... allows the patient to position them in ... make the penis rigid enough for sexual ...
Medicine Products: